

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 CANCELED

13. (NEW) A controlled release anti-emetic composition comprising lorazepam, diphenhydramine, promethazine, and metoclopramide.

14. (NEW) The controlled release anti-emetic composition according to claim 13 further comprising a pharmaceutically acceptable carrier.

15. (NEW) The controlled release anti-emetic composition according to claim 13 wherein said composition is formulated into a depot.

16. (NEW) The controlled release anti-emetic composition according to claim 15 wherein said depot is an injectable depot.

17. (NEW) The controlled release anti-emetic composition according to claim 16 wherein said injectable depot is a 1-, 3- or 6-month depot.

18. (NEW) The controlled release anti-emetic composition according to claim 15 wherein composition is administered transdermally.

19. (NEW) An inhalable anti-emetic composition comprising lorazepam, diphenhydramine, promethazine, and metoclopramide.

20. (NEW) A method of treating or inhibiting emesis in a patient comprising administering to said patient an anti-emetic effective amount of an anti-emetic composition according to either of claims 13 or 19.

21. (NEW) A controlled release anti-emetic composition comprising at least one antihistamine, at least one anti-dopaminergic, and at least one anti-anxiety agent.

22. (NEW) An inhalable anti-emetic composition comprising at least one antihistamine, at least one anti-dopaminergic, and at least one anti-anxiety agent.